secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0000950170-23-027262
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics reports 2023 annual meeting voting results
------------------------------------------------------------

- Elected Class I directors Epstein, Mendlein, Jooss with >65.8M 'for' votes each; 10.2M broker non-votes.
- Ratified Ernst & Young as auditor for FY2023: 85.5M for, 0.2M against, 1.2M abstentions.
- Approved non-binding advisory vote on executive compensation: 73.7M for, 3.0M against, 0.1M abstentions.
- Total shares present at meeting: 86.9M of 98.2M outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023027262/0000950170-23-027262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023027262/fate-20230606.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer